drugset
drugset / Trial / NCT03992339

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03992339 ↗

Phase 2 Completed 60 enrolled Antengene Corporation
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Timeline

Start
2020-04-09
Primary completion
2023-05-31
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 60 mg Oral

Indications

diffuse large B-cell lymphoma